Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Towa Pharmaceutical Co Ltd (JP:4553)

TSE/TYO:4553

4553

Towa Pharmaceutical Co

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding JP:4553?

Track your performance easily

Link Broker

Towa Pharmaceutical Co (4553) Stock Price & Analysis

0 Followers

4553 Stock Chart & Stats

Advanced Chart >

Day’s Range¥0 - ¥0

52-Week Range¥2,223.00 - ¥3,240.00

Previous Close¥2,821

Volume84.00K

Average Volume (3M)86.66K

Market Cap

¥138.83B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)8.8

Beta0.49

Next Earnings

Feb 18, 2025

EPS EstimateN/A

Next Dividend Ex-Date

Mar 28, 2025

Dividend Yield2.2%

Share Statistics

EPS (TTM)320.50

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. Volume86,655

Standard DeviationN/A

R-SquaredN/A

AlphaN/A

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥3,193.03

Price Target Upside13.19% Upside

Rating ConsensusHold

Number of Analyst Covering1

Towa Pharmaceutical Co News

PremiumCompany Announcements

Towa Pharmaceutical Reports Strong Sales but Decline in Profit

11d ago

PremiumPre-Earnings

TWAPF Earnings this Week: How Will it Perform?

13d ago

PremiumCompany Announcements

Towa Pharmaceutical Boosts Financial Forecasts for 2025

18d ago

PremiumCompany Announcements

Towa Pharmaceutical Settles Patent Infringement Suit

2M ago

PremiumCompany Announcements

Towa Pharmaceutical Expands and Revises Earnings Forecast

4M ago

PremiumCompany Announcements

Towa Pharmaceutical Reports Strong Q1 2024 Growth

4M ago

PremiumCompany Announcements

Towa Pharmaceutical Raises Profit Forecasts

4M ago

PremiumCompany Announcements

Towa Pharmaceutical Finalizes Restricted Stock Compensation

4M ago

See More TWAPF News >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

7.34% Mutual Funds

― Other Institutional Investors

90.19% Public Companies and

Individual Investors

Detailed Ownership Overview >

4553 FAQ

What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?

Towa Pharmaceutical Co Ltd lowest stock price was ¥2223.00 and its highest was ¥3240.00 in the past 12 months.

What is Towa Pharmaceutical Co Ltd’s market cap?

Currently, no data Available

When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?

Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Feb 18, 2025 which is in 87 days.

How were Towa Pharmaceutical Co Ltd’s earnings last quarter?

Towa Pharmaceutical Co Ltd released its earnings results on Nov 12, 2024. The company reported ¥21.53 earnings per share for the quarter, missing the consensus estimate of ¥49.616 by -¥28.086.

Is Towa Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Towa Pharmaceutical Co Ltd pay dividends?

Towa Pharmaceutical Co Ltd pays a Annually dividend of ¥30 which represents an annual dividend yield of 2.2%. See more information on Towa Pharmaceutical Co Ltd dividends here

What is Towa Pharmaceutical Co Ltd’s EPS estimate?

Towa Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Towa Pharmaceutical Co Ltd have?

Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.

What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?

Towa Pharmaceutical Co Ltd reported an EPS of ¥21.53 in its last earnings report, missing expectations of ¥49.616. Following the earnings report the stock price went up 0.486%.

Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in JP:4553

---

Towa Pharmaceutical Co Stock Smart Score

Unlock Smart Score

Analyst Consensus

Hold

Average Price Target:
¥3,193.03 (13.19% Upside)

Technicals

Fundamentals

Return on Equity

9.98%

Trailing 12-Months

Asset Growth

17.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Towa Pharmaceutical Co Ltd

TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.

---

4553 Stock 12 Month Forecast

Average Price Target

¥3,193.03

▲(13.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2305":"¥2,305","2527":"¥2,527","2749":"¥2,749","2971":"¥2,971","3193":"¥3,193"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3192.2878064152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3193.033877,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3192.2878064152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.19K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2305,2527,2749,2971,3193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2821,2849.560600493477,2878.1212009869537,2906.6818014804307,2935.242401973908,2963.8030024673844,2992.3636029608615,3020.9242034543386,3049.4848039478156,3078.0454044412922,3106.6060049347693,3135.1666054282464,3163.727205921723,{"y":3192.2878064152,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2821,2849.6179905384615,2878.235981076923,2906.8539716153846,2935.471962153846,2964.0899526923076,2992.707943230769,3021.3259337692307,3049.943924307692,3078.5619148461537,3107.1799053846153,3135.797895923077,3164.4158864615383,{"y":3193.033877,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2821,2849.560600493477,2878.1212009869537,2906.6818014804307,2935.242401973908,2963.8030024673844,2992.3636029608615,3020.9242034543386,3049.4848039478156,3078.0454044412922,3106.6060049347693,3135.1666054282464,3163.727205921723,{"y":3192.2878064152,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2415.909,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2306.095,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2568.865,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2697.308,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2802.832,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2773.12,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2862.256,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2926.632,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2852.352,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2876.121,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3070,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3085,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2821,"date":1732233600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >